Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Pull outdoes puncture technique for endoscopic gastrostomy

Audrey Abella
06 Mar 2018

Using the pull technique over the puncture approach in the placement of a percutaneous endoscopic gastrostomy (PEG) resulted in fewer short-term adverse events (AEs) for patients with malignant upper gastrointestinal (GI) tract tumours, according to a study.

A total of 120 patients (median age 64 years, 85 percent male) with histologically confirmed, endoscopically passable (external diameter 8.7 mm) malignant epithelial tumours of the upper GI tract or larynx were randomized for PEG placement using either the conventional pull approach (n=58) or a novel direct puncture device (n=62). Follow-up for early AEs was done on days 3, 7, and 21 postintervention. For late AEs, follow-up was carried out after 1, 3, and 6 months, with a final follow-up 5 years postintervention.

At 1 month, there was a significantly higher incidence of rubor and pain at the placement site with the puncture vs the pull technique (18 vs 4; p=0.004 and 5 vs 0; p=0.059, respectively). [Endosc Int Open 2018;06:E29-E35]

Six months following PEG placement, inflammation and dislocation were more commonly observed with the puncture vs the pull arm (21.0 percent vs 15.5 percent; p=0.0011).

The findings were lower than that reported in a retrospective Korean study showing a high rate of PEG inflammation (81.1 percent) in all patients. [Surg Endosc 2013;27:3806-3815; Aliment Pharmacol Ther 2003;18:209-215] The researchers attributed this difference to the strict prophylactic antibiotic supplementation and standard protocol employed in the current study.

Patients with malignant upper GI tract tumours are at risk of weight loss due to impaired chewing and swallowing, with early supportive nutrition therapy recommended to mitigate malnutrition and improve prognosis, said the researchers. This would usually require PEG placement especially if low nutrient supply is expected to go beyond 3 weeks, [Clin Nutr 2006;25:245-259] with PEG favoured over nasoenteric systems given its sustainability and longer turnaround time.

The researchers initially postulated that direct puncture would fare better given the lack of direct contact between the PEG device and the upper GI tract microbiome. However, direct puncture entails a longer procedure time due to the additional gastropexies besides the PEG, noted the researchers.

Overall, the findings favoured the pull over the puncture technique for PEG application, with subgroup results illustrating a faster execution with the pull technique among low-weight patients with sparse visceral fat and less obstructive T1 tumours, said the researchers.

“Obstruction of the upper [GI] tract is a relevant factor for the pull technique as all tumours had to be passable by a standard gastroscope as per protocol,” they said.

Glucose tolerance, which was not evaluated in this trial, could be an important parameter that needs to be included in future trials as uncontrolled diabetes could also influence wound infection, they added.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).